📰 Urinary News
Page 7 - Urinary News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Urinary. Real-time updates on events, politics, business and more.
November 19, 2022
Dr Rubina Shanawaz, Consultant Gynecologist, Fortis Hospital, stated that one in four women in India above the age of 35 face some kind of urinary leakage. The common misconception is that it is a part of having given birth to children and due to the ageing process. Also, it is a fact that women are embarrassed to bring it up to their families and seek treatment options for the same, she said.In B
November 3, 2022
By Ian Walker GSK PLC said Thursday that it will stop patient recruitment early for two trials of gepotidacin, a treatment for urinary tract infections, following a recommendation by the... | November 3, 2022
November 2, 2022
According to Fortune Business Insights, the global Europe urinary drainage bags market size is projected to reach USD 757.6 Million by 2029, at CAGR of...
October 30, 2022
According to an international study conducted by a Rutgers expert comparing new and older medicines for complicated urinary tract infections, a new medicine combination has been found to be more effective, particularly against chronic, drug-resistant infections.
October 26, 2022
A new drug combination has been found to be more effective, especially against persistent, drug-resistant infections, according to an international study conducted by a Rutgers expert comparing new and older therapies for complex urinary tract infections.
October 26, 2022
Some 79 percent of the patients receiving the new combination of cefepime and enmetazobactam were successfully treated for their illness, as opposed to 58.9 percent of those receiving the conventional treatment of piperacillin and tazobactam.
October 18, 2022
Dust plumes observed being ‘pushed’ into interstellar space by intense starlight
October 7, 2022
WASHINGTON (dpa-AFX) - Alnylam Pharmaceuticals Inc. (ALNY) said that the U.S. Food and Drug Administration approved a label expansion for Oxlumo (lumasiran), an RNAi therapeutic administered via
October 4, 2022
Patent issuance further strengthens Viveve's intellectual property portfolio for the treatment of female stress urinary incontinenceENGLEWOOD, CO / ACCESSWIRE / October 4, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE)
September 27, 2022
New branding reflects Company's vision to be the leader in the treatment of Stress Urinary Incontinence in WomenCompletion of PURSUIT follow-up visits anticipated by the end of 2022 with topline results